论文部分内容阅读
目的 :回顾性分析前列腺癌应用192 铱组织间插植合并外照射 ,直肠内敷贴合并外照两种近距离放疗和激素合并免疫治疗法疗效。方法 :4 1例前列腺癌患者分三组 :(甲组 ) :11例采用192 铱组织间插植合并外照射 ;(乙组 ) :18例采用192 铱直肠内敷贴合并外照射 ;(丙组 ) :12例采用雌激素加免疫治疗。结果 :4年的生存率 :甲组 :81 82 % ( 9/11) ;乙组 :66 67% ( 12 /18) ;丙组 :5 0 0 0 % ( 6/12 ) ;合计 :65 85 % ( 2 7/4 1)。结论 :早期的前列腺癌可用192 铱组织间插植近距离放疗合并外照射 ,较晚期的前列腺癌用192 铱直肠内敷贴近距离放疗合并外照射 ,而晚期的前列腺癌则用雌激素加免疫治疗
OBJECTIVE: To retrospectively analyze the efficacy of 192 iridium interplanting combined with external irradiation and intrarectal application with two types of brachytherapy and hormone combination immunotherapy in prostate cancer. Methods: 41 cases of prostate cancer patients were divided into three groups: (group A): 11 cases with 192 iridium interplanting with external irradiation; (group B): 18 cases with 192 iridium rectal application combined with external irradiation; Group): 12 cases of estrogen plus immunotherapy. Results: Four-year survival rates: Group A: 81 82% (9/11); Group B: 66 67% (12/18); Group C: 500% (6/12); Total: 65 85 % (2 7/4 1). CONCLUSIONS: 192 Iridium tissue interstitial brachytherapy combined with external radiation can be used in early stage prostate cancer, 192 Iridium rectum with brachytherapy combined with external radiation for the later stage of prostate cancer, and estrogen plus immunotherapy in advanced stage prostate cancer